OriGene Technologies, Inc., announced February 2nd that it has entered into a multi-year antibody development collaboration featuring its proprietary UltraMAB™ technology platform and granted to Dako, an Agilent Technologies company (Santa Clara, CA), a worldwide non-exclusive commercial license to OriGene's mouse anti-ALK monoclonal antibody clone OTI1A4 for research and diagnostics use within the immunocytochemistry and immunohistochemistry fields.
Rockville, MD (PRWEB) February 04, 2016
OriGene Technologies, Inc., announced February 2nd that it has entered into a multi-year antibody development collaboration featuring its proprietary UltraMAB™ technology platform and granted to Dako, an Agilent Technologies company (Santa Clara, CA), a worldwide non-exclusive commercial license to OriGene's mouse anti-ALK monoclonal antibody clone OTI1A4 for research and diagnostics use within the immunocytochemistry and immunohistochemistry fields.
The OTI1A4 clone licensed by Dako was developed from OriGene's proprietary UltraMAB antibody development platform and verified to an unprecedented "mono-specificity" level, ensuring superior performance in tissue evaluations and in antibody dependent applications such as immunohistochemistry (IHC).
UltraMAB Antibody Technology Overview:
Initiated in 2010, OriGene's UltraMAB antibody development and validation program has successfully released more than 150 "Ultra-Specific" antibodies, each validated against greater than 17,000 human protein antigens or 85% of the human proteome, and meticulously tested on the company's high-density protein microarray technology. Through this unique validation approach, each UltraMAB Antibody is performance tested and specificity-verified to possess no discernable cross-reactivity with unrelated proteins.
As research data from many groups have shown that some antibodies on the commercial market are not truly mono-specific and similar epitopes are sometimes found across multiple proteins of related molecular weight, UltraMAB Antibodies effectively solve the challenge associated with the use of poorly performing or "highly-cross-reactive" antibody markers in clinical evaluations involving tissue. The use of UltraMAB antibodies results in the reduction of unexpected side effects or false diagnostic results. As a result of confirmed high-specificity and affinity, UltraMAB antibodies are best in class solutions for use in diagnostic and therapeutic applications, such as IHC and Flow cytometry.
"We are pleased to work with Dako on this exciting endeavor and to expand our strategic relationship by providing the global anatomical pathology community a series of ‘ultra-specific' cutting-edge IHC antibodies, such as the ALK OTI1A4 antibody marker that will be an important tool in the detection of ALK rearrangements in cancer patients. We believe this partnership further demonstrates OriGene's unique capabilities as a leading reagent manufacturer and will allow UltraMAB® antibodies to continue to contribute to the advancement of personalized cancer diagnostics and ultimately improve human health on a global scale," said Wei-Wu He, Chairman and CEO of OriGene Technologies.
While no commercial launch date from Dako for the ALK clone has been announced, the license grant is anticipated to be the first of many new releases of antibody markers from this collaboration. "We are excited about expanding our portfolio of antibodies through this partnership, further underlining Dako leadership within anatomical pathology," said Andreas Hoel, Senior Director, Portfolio Management, Pathology at Agilent. Additional information about UltraMAB, a full list of available released products, and an overview of Dako's antibodies can be found at http://www.origene.com/UltraMAB or http://www.dako.com.
About OriGene Technologies
OriGene Technologies, Inc. is a gene centric life sciences company dedicated to support academic, diagnostic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 12,000 purified human proteins produced from mammalian (HEK293) cells, over 50,000 high quality primary antibodies including TrueMAB™ mouse monoclonal antibodies and polyclonal antibodies made against full-length proteins for the conservation of native epitopes, validated "mono-specific" monoclonal antibodies called UltraMAB® which offer a unique solution to the critical issue of antibody specificity, >140,000 highly validated human tissues, and protein microarray products and services. For more information, visit http://www.origene.com.
About Agilent Technologies and Dako
Agilent Technologies Inc. A, a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide. In 2012, Agilent acquired Dako, a well-known provider of reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Information about Agilent is available at http://www.agilent.com, and information about Dako products is available at http://www.dako.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2016/02/prweb13195759.htm
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
